About Sonnet BioTherapeutics


Sonnet BioTherapeutics is a discovery-focused biotech company developing a pipeline of bi- and tri-functional therapies that can stimulate and/or block immune-modulating targets to control cancer cells.

Sonnet BioTherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies.

The company is led by experienced scientists who played prominent roles in the discovery and early development of the first wave of cancer immunotherapeutics developed by Bristol-Myers Squibb and Medarex. In our 4+ years of operation, Sonnet has recruited a small but experienced team of hands-on scientists that have made significant progress in advancing our pipeline.

Sonnet Mission

Sonnet BioTherapeutics is a platform enabled proof-of-concept engine created to generate innovative and IND-worthy immuno-oncology candidates.

We are leveraging a unique IP driven platform:

  • Single domain antibody fragment platform (ScFv and VhH)
  • Enhanced pharmacokinetics and targeting of the tumor environment via albumin delivery
  • Validated targets, initially focused on rH-cytokines
  • Dual targeting feasible – combination Immune Oncology therapeutics engineered into a single product
  • Able to activate and sustain an immune response selectively against tumors
  • Modular scaffold that can be customized to yield a broad family of multi-targeted therapeutics.